company background image
CSBR

Champions Oncology NasdaqCM:CSBR Stock Report

Last Price

US$9.47

Market Cap

US$128.1m

7D

8.6%

1Y

-12.2%

Updated

14 Aug, 2022

Data

Company Financials +
CSBR fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance4/6
Financial Health6/6
Dividends0/6

CSBR Stock Overview

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States.

Champions Oncology Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Champions Oncology
Historical stock prices
Current Share PriceUS$9.47
52 Week HighUS$11.00
52 Week LowUS$6.81
Beta0.91
1 Month Change16.34%
3 Month Change30.62%
1 Year Change-12.23%
3 Year Change53.24%
5 Year Change196.87%
Change since IPO-21.08%

Recent News & Updates

Jul 21

Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M

Champions Oncology press release (NASDAQ:CSBR): Q4 Non-GAAP EPS of -$0.02. Revenue of $12.9M (+21.7% Y/Y).

Shareholder Returns

CSBRUS Life SciencesUS Market
7D8.6%1.9%3.2%
1Y-12.2%-19.8%-10.2%

Return vs Industry: CSBR exceeded the US Life Sciences industry which returned -19.8% over the past year.

Return vs Market: CSBR underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is CSBR's price volatile compared to industry and market?
CSBR volatility
CSBR Average Weekly Movement6.8%
Life Sciences Industry Average Movement11.0%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: CSBR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: CSBR's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1985230Ronnie Morrishttps://www.championsoncology.com

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice.

Champions Oncology Fundamentals Summary

How do Champions Oncology's earnings and revenue compare to its market cap?
CSBR fundamental statistics
Market CapUS$128.06m
Earnings (TTM)US$548.00k
Revenue (TTM)US$49.11m

233.7x

P/E Ratio

2.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CSBR income statement (TTM)
RevenueUS$49.11m
Cost of RevenueUS$23.63m
Gross ProfitUS$25.48m
Other ExpensesUS$24.93m
EarningsUS$548.00k

Last Reported Earnings

Apr 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.041
Gross Margin51.88%
Net Profit Margin1.12%
Debt/Equity Ratio0%

How did CSBR perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CSBR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CSBR?

Other financial metrics that can be useful for relative valuation.

CSBR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.6x
Enterprise Value/EBITDA57.5x
PEG Ratio2.5x

Price to Sales Ratio vs Peers

How does CSBR's PS Ratio compare to its peers?

CSBR PS Ratio vs Peers
The above table shows the PS ratio for CSBR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.8x
CDXC ChromaDex
1.7x21.1%US$115.8m
LAB Standard BioTools
1.2xn/aUS$138.4m
HBIO Harvard Bioscience
1.1x9.8%US$136.6m
TKNO Alpha Teknova
3.3x20.7%US$140.7m
CSBR Champions Oncology
2.6x16.6%US$128.1m

Price-To-Sales vs Peers: CSBR is expensive based on its Price-To-Sales Ratio (2.6x) compared to the peer average (1.8x).


Price to Earnings Ratio vs Industry

How does CSBR's PE Ratio compare vs other companies in the US Life Sciences Industry?

Price-To-Sales vs Industry: CSBR is good value based on its Price-To-Sales Ratio (2.6x) compared to the US Life Sciences industry average (5x)


Price to Sales Ratio vs Fair Ratio

What is CSBR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CSBR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.6x
Fair PS Ratio2.1x

Price-To-Sales vs Fair Ratio: CSBR is expensive based on its Price-To-Sales Ratio (2.6x) compared to the estimated Fair Price-To-Sales Ratio (2.1x).


Share Price vs Fair Value

What is the Fair Price of CSBR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CSBR ($9.47) is trading below our estimate of fair value ($31.37)

Significantly Below Fair Value: CSBR is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Champions Oncology forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


92.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CSBR's forecast earnings growth (92% per year) is above the savings rate (1.9%).

Earnings vs Market: CSBR's earnings (92% per year) are forecast to grow faster than the US market (14.5% per year).

High Growth Earnings: CSBR's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CSBR's revenue (16.6% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: CSBR's revenue (16.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CSBR's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Champions Oncology performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


60.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CSBR has high quality earnings.

Growing Profit Margin: CSBR's current net profit margins (1.1%) are higher than last year (0.9%).


Past Earnings Growth Analysis

Earnings Trend: CSBR has become profitable over the past 5 years, growing earnings by 60.6% per year.

Accelerating Growth: CSBR's earnings growth over the past year (51.4%) is below its 5-year average (60.6% per year).

Earnings vs Industry: CSBR earnings growth over the past year (51.4%) exceeded the Life Sciences industry 15.6%.


Return on Equity

High ROE: CSBR's Return on Equity (6%) is considered low.


Discover strong past performing companies

Financial Health

How is Champions Oncology's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: CSBR's short term assets ($19.7M) exceed its short term liabilities ($17.5M).

Long Term Liabilities: CSBR's short term assets ($19.7M) exceed its long term liabilities ($8.8M).


Debt to Equity History and Analysis

Debt Level: CSBR is debt free.

Reducing Debt: CSBR has not had any debt for past 5 years.

Debt Coverage: CSBR has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CSBR has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Champions Oncology current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CSBR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CSBR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CSBR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CSBR's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CSBR has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Ronnie Morris (56 yo)

5.58yrs

Tenure

US$775,000

Compensation

Dr. Ronnie Morris, M.D. has been Chief Executive Officer at Champions Oncology, Inc. since January 31, 2017 and its President since 2021. Dr. Morris previously served as the President and a Director of Cha...


CEO Compensation Analysis

Compensation vs Market: Ronnie's total compensation ($USD775.00K) is about average for companies of similar size in the US market ($USD759.99K).

Compensation vs Earnings: Ronnie's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CSBR's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

Experienced Board: CSBR's board of directors are seasoned and experienced ( 11.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Champions Oncology, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Champions Oncology, Inc.
  • Ticker: CSBR
  • Exchange: NasdaqCM
  • Founded: 1985
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$128.058m
  • Shares outstanding: 13.52m
  • Website: https://www.championsoncology.com

Number of Employees


Location

  • Champions Oncology, Inc.
  • One University Plaza
  • Suite 307
  • Hackensack
  • New Jersey
  • 7601
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/14 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/04/30
Annual Earnings2022/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.